Shares of Lexaria Bioscience Corp. (OTCMKTS:LXRP – Get Free Report) fell 10.7% during trading on Monday . The stock traded as low as $0.21 and last traded at $0.22. 2,151,500 shares changed hands during trading, an increase of 254% from the average session volume of 608,350 shares. The stock had previously closed at $0.25.
Lexaria Bioscience Stock Performance
The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.01 and a current ratio of 8.52. The firm’s 50-day moving average price is $0.22.
About Lexaria Bioscience
Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries.
Featured Stories
- Five stocks we like better than Lexaria Bioscience
- What is a buyback in stocks? A comprehensive guide for investors
- High-Yield Texas Instruments Could Hit New Highs Soon
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Best Aerospace Stocks Investing
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Lexaria Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexaria Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
